Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

David Ross, Andrew Wilson, Tara Cochrane, William Stevenson, James Liang, Marco Brociner, Francesca Palandri, Stephen Larsen, Merit Hanna, Alessandro Maria Vannucchi, Kristen Pettit, Natalia Curto-Garcia, Harinder Gill, Uche Okoro, Jonas Jutzi, Patricia Marinello, Monia Marchetti

Blood (2025) 146 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2025-2033

Published: 2025

Journal Articles

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

Vivian Li, Rita Yim, Paul Lee, Qi Zhang, Lynn Chin, Po Yan Chan, Chun Kei Au, Sharon Shi, Lester Au, Carmen Lee, Tony Wu, Garret Leung, Yok-Lam Kwong, Harinder Gill

Blood (2025) 146 (Supplement 1): 2041.

https://doi.org/10.1182/blood-2025-2041

Published: 2025

Journal Articles

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

Harinder Gill, Farhad Ravandi, Jessica Altman, Gail Roboz, Tony Wu, Garret Leung, Danelle James, Stephane Berthier, Yok-Lam Kwong

Blood (2025) 146 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2025-1506

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Blood (2025) 146 (Supplement 1): 907.

https://doi.org/10.1182/blood-2025-907

Published: 2025

Journal Articles

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Aniket Bankar, Andrew Kuykendall, Naveen Pemmaraju, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentín García Gutiérrez, Harinder Gill, Joseph Scandura, Francesca Palandri, Matthew Reaney, Cristina Ivanescu, Christina Daskalopoulou, Phil Dinh, Sarita Khanna, Suneel Gupta, Arturo Molina, David Cella

Blood (2025) 146 (Supplement 1): 5588.

https://doi.org/10.1182/blood-2025-5588

Published: 2025

Journal Articles

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Abdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, Weichung Joe Shih, Waleed Da'na, Tsewang Tashi, Oleh Zagrijtschuk, Robert Geller, Harinder Gill

Blood (2024) 144 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2024-199337

Published: 2024

Journal Articles

Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Harinder Gill, Lester Au, Dorothy Tsai, Rita Yim, Vivian Li, Paul Lee, Lynn Chin, Qi Zhang, Garret Man Kit Leung, Tony Kwun Yat Wu, Hugh Young Rienhoff, Jr.

Blood (2024) 144 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2024-208038

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

Results of the Regimen Dime in Diffuse Large B-Cell Lymphoma with MYC over-Expression: A Retrospective Analysis

Tony Kwun Yat Wu, Thomas S Chan, Yu Yan Hwang, Karen Hoi Ki Tang, Garret Man Kit Leung, Carmen Lee, Harinder Gill, Eric Tse, Yok Lam Kwong

Blood (2024) 144 (Supplement 1): 6464.

https://doi.org/10.1182/blood-2024-204629

Published: 2024

Journal Articles

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood (2024) 144 (Supplement 1): 4569.3.

https://doi.org/10.1182/blood-2024-200881

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Harinder Gill, Chul Won Choi, Hein Than, Hsin-An Hou, Chul Won Jung, Yok-Lam Kwong, Garret M. K. Leung, Melissa G. M. Ooi, Ponlapat Rojnuckarin, David M. Ross, Lee-Yung Shih, Katsuto Takenaka, Winnie Z. Y. Teo, Keita Kirito

Blood (2024) 144 (Supplement 1): 3678.

https://doi.org/10.1182/blood-2024-201402

Published: 2024

Journal Articles

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Melissa Ooi, Zhentang Lao, Harinder Gill, Yasmin Abaza, Maximilian Stahl, Tamanna Haque, Amy E. DeZern, Peter L. Greenberg, Marc Pelletier, Arti Singh, Daniel Carreon, Valerie Beaulieu, Janghee Woo

Blood (2023) 142 (Supplement 1): 3250.

https://doi.org/10.1182/blood-2023-174642

Published: 2023

Journal Articles

A Clinical-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in Asia - a Multicenter Study of the Asian Myeloid Working Group (AMWG)

Harinder Gill, Hsin An Hou, Paul Lee, Rita Yim, Xavier Cheng-Hong Tsai, Melissa Ooi, Tsz-Shing Hui, Radha Raghupathy, Lynn Chin, Lester Au, Vivian Li, Garret Man Kit Leung, Edmond Ma, Asif Javed, Ho-Wan Ip, Wee-Joo Chng, Wen-Chien Chou, Hwei-Fang Tien, Yok-Lam Kwong

Blood (2023) 142 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2023-182750

Published: 2023

Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood (2023) 142 (Supplement 1): 747.

https://doi.org/10.1182/blood-2023-179329

Published: 2023

Journal Articles

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Albert Chun Fung Sin, Hsin An Hou, Chih-Cheng Chen, Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2023-180922

Published: 2023

Journal Articles

An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

Harinder Gill, Rita Yim, Lynn Chin, Paul Lee, Vivian Li, Lester Au, Garret Man Kit Leung, Ka Leung Daniel Cheuk, Shau-Yin Ha, Chi Kong Li, Melissa Ooi, Wee-Joo Chng, Patrick Chu, Cyrus Kumana, Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 157.

https://doi.org/10.1182/blood-2023-179644

Published: 2023

Journal Articles

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Rock Yuk Yan Leung, Elaine Lee, Hugh Young Rienhoff Jr., Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 621.

https://doi.org/10.1182/blood-2023-181971

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Results of the Regimen Dime in Diffuse Large B-Cell Lymphoma with MYC over-Expression: A Retrospective Analysis

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

A Clinical-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in Asia - a Multicenter Study of the Asian Myeloid Working Group (AMWG)

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only